Christopher P. Evans MD, FACS

Dr. Evans has maintained an active research lab by obtaining peer-reviewed funding from DOD and NIH sources. His basic science research focuses on neuropeptides mediated signal transduction in prostate cancer. He has made several novel observations to include signaling molecules, which can activate the androgen receptor in an androgen-free environment. This promotes the early transition to androgen-independent prostate cancer. He identified Src kinase as a potential target against which he is using a novel drug known as AZD0530 which has significant inhibitory effect on this molecule.